These disease links involving the RhoGEF activity of AKAP-Lbc suggest that inhibitors of the RhoA–AKAP-Lbc interaction may be a worthwhile line of investigation for treatment of cardiac hypertrophy, pulmonary arterial hypertension [34] and possibly for cancers. The gene discussed is AKAP13; the disease is pulmonary arterial hypertension.